Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y
J Pharmacol Exp Ther. 1984 Apr;229(1):226-30.
A new aldose reductase inhibitor, ONO-2235 [(E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene] rhodanine], was found to possess a potent inhibitory activity of aldose reductase, partially purified from rat lens (IC50 = 1.0 X 10(-8) M) and human placenta (IC50 = 2.6 X 10(-8) M). Against rat lens aldose reductase, ONO-2235 exhibited uncompetitive inhibition as previously observed with 7-hydroxy-4-oxo-4H-chromen-2-carboxylic acid. Sorbitol accumulation in the isolated rat lenses, sciatic nerves and human erythrocytes were all effectively inhibited during incubation with high concentrations of glucose (28-50 mM) by ONO-2235 at a concentration of about 10(-6) M. Because the accumulation of sorbitol has been reported to play an etiological role in the development of diabetic complications, the results suggest that ONO-2235 may prove to be useful in preventing and improving some diabetic complications.
一种新的醛糖还原酶抑制剂ONO - 2235 [(E)-3 - 羧甲基 - 5 - [(2E)-甲基 - 3 - 苯基亚丙基]若丹宁],被发现对从大鼠晶状体(IC50 = 1.0×10⁻⁸ M)和人胎盘(IC50 = 2.6×10⁻⁸ M)中部分纯化得到的醛糖还原酶具有强大的抑制活性。对于大鼠晶状体醛糖还原酶,ONO - 2235表现出非竞争性抑制,这与之前观察到的7 - 羟基 - 4 - 氧代 - 4H - 色烯 - 2 - 羧酸的情况相同。在与高浓度葡萄糖(28 - 50 mM)一起孵育期间,浓度约为10⁻⁶ M的ONO - 2235能有效抑制分离的大鼠晶状体、坐骨神经和人红细胞中的山梨醇积累。由于据报道山梨醇的积累在糖尿病并发症的发生中起病因学作用,这些结果表明ONO - 2235可能被证明对预防和改善某些糖尿病并发症有用。